This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on ISI (8)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Immunization  • Alert me on articles by topic

Matthew M. Davis, MD, MAPP

JAMA. 2005;294:845-846.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Has varicella vaccination been as cost-effective as anticipated when it was universally recommended for children 10 years ago? The answer is complicated and illuminates an evolving controversy regarding the role of cost-effectiveness analyses in deliberations over national vaccine recommendations.

In 1994, Lieu and colleagues¹ estimated the cost-effectiveness of a universal childhood varicella vaccination program. Projecting a national vaccination rate of 97% by the sixth year of the program, they estimated a 94% reduction in varicella incidence, accompanied by an 89% reduction in direct medical costs. Accounting as well for reductions in the quantity of parents’ and other adults’ lost work time attributable to varicella (ie, the "indirect" benefits of vaccination), Lieu et al projected that a varicella vaccination program would save more than $5 for every $1 spent.¹

These projections of reduced varicella disease burden and direct medical costs with varicella vaccination appear prescient, even . . . [Full Text of this Article]

Author Affiliations: Child Health Evaluation and Research Unit, Division of General Pediatrics, Division of General Internal Medicine, and the Gerald R. Ford School of Public Policy, University of Michigan, Ann Arbor.

RELATED ARTICLE

Impact of Varicella Vaccination on Health Care Utilization
Fangjun Zhou, Rafael Harpaz, Aisha O. Jumaan, Carla A. Winston, and Abigail Shefer
JAMA. 2005;294(7):797-802.
ABSTRACT | FULL TEXT